# External Validation Audit

- Paper ID: 3
- Title: Regression of multifocal in transit melanoma metastases after palliative resection of dominant masses and 2 years after treatment with ipilimumab
- Validation-set rule: record mismatches without adapting ontology, schema, rule, or prompts.

# Case Summary

- Patient identifier: an 84-year-old man
- Age / sex: 84 / man
- Melanoma subtype: cutaneous melanoma
- Primary site: right lower extremity
- Stage: NOT STORED
- Metastatic sites: cutaneous and subcutaneous right lower extremity; in transit right lower extremity
- First observed reduction: By November 2014
- Regression confirmation: NOT STORED
- Regression extent: UNCERTAIN
- Treatment before regression: 4 cycles of ipilimumab between December 2012 and February 2013; palliative resections in February 2014 and August 2014
- Preceding events: palliative resection of dominant nodule in February 2014; postoperative wound dehiscence and recurring infections; palliative resection of right medial knee nodule in August 2014
- Outcome: complete clinical and radiographic response; all in transit metastases resolved

## Case Field Statuses

- patient_identifier: REPORTED | raw value: an 84-year-old man
- age: REPORTED | raw value: 84
- sex: REPORTED | raw value: man
- melanoma_subtype: REPORTED | raw value: cutaneous melanoma
- primary_site: REPORTED | raw value: right lower extremity
- stage: NOT_REPORTED | raw value: None
- metastatic_sites: REPORTED | raw value: ['cutaneous and subcutaneous right lower extremity', 'in transit right lower extremity']
- diagnosis_date: REPORTED | raw value: October of 2012
- regression_start_date: NOT_REPORTED | raw value: None
- first_observed_reduction: REPORTED | raw value: By November 2014
- regression_confirmed_date: REPORTED | raw value: By August 2016
- regression_duration: NOT_REPORTED | raw value: None
- regression_type: REPORTED | raw value: spontaneous regression
- regression_extent_clinical: UNCERTAIN | raw value: UNCERTAIN
- viable_tumor_at_pathology: REPORTED | raw value: PRESENT
- treatment_before_regression: REPORTED | raw value: 4 cycles of ipilimumab between December 2012 and February 2013; palliative resections in February 2014 and August 2014
- treatment_status: REPORTED | raw value: treatment_completed
- preceding_events: REPORTED | raw value: ['palliative resection of dominant nodule in February 2014', 'postoperative wound dehiscence and recurring infections', 'palliative resection of right medial knee nodule in August 2014']
- outcome: REPORTED | raw value: complete clinical and radiographic response; all in transit metastases resolved
- follow_up_duration: NOT_REPORTED | raw value: None

# Timeline

## Event 167: tumor_progression
- Description: Right-leg cutaneous lesions had been growing in size for the preceding 3 years.
- Event date: NONE
- Relative time: over the preceding 3 years before October 2012
- Stored/source precision: unknown / RELATIVE
- Relation to regression: BEFORE
  - Evidence 961: page 1, section Case Presentation, type OBSERVED_FACT
  - Quote: "The lesions had been growing in size over the preceding 3 years (Fig. 1a)."

## Event 168: diagnosis
- Description: An 84-year-old man presented with multiple cutaneous nodules on his right leg.
- Event date: NONE
- Relative time: NONE
- Stored/source precision: unknown / APPROXIMATE
- Relation to regression: BEFORE
  - Evidence 962: page 1, section Case Presentation, type OBSERVED_FACT
  - Quote: "In October of 2012 an 84-year-old man with a history of coronary artery disease, COPD, hypertension, and venous insufficiency presented with multiple cutaneous nodules on his right leg."

## Event 169: biopsy
- Description: An excisional biopsy revealed malignant melanoma with focal necrosis.
- Event date: NONE
- Relative time: NONE
- Stored/source precision: unknown / UNKNOWN
- Relation to regression: BEFORE
  - Evidence 963: page 1, section Case Presentation, type OBSERVED_FACT
  - Quote: "An excisional biopsy was performed and revealed a malignant melanoma with focal necrosis."

## Event 170: metastasis
- Description: PET/CT demonstrated a dominant mass lateral to the right fibular head and numerous nodules from the right mid thigh to the ankle, compatible with multiple cutaneous and subcutaneous melanoma metastases; no distant metastatic disease was evident.
- Event date: NONE
- Relative time: NONE
- Stored/source precision: unknown / UNKNOWN
- Relation to regression: BEFORE
  - Evidence 964: page 1, section Case Presentation, type OBSERVED_FACT
  - Quote: "A PET/CT of the entire body demonstrated a dominant soft tissue mass lateral to the right fibular head with numerous additional soft tissue nodules extending from the right mid thigh anteriorly to the level of the ankle, compatible with multiple cutaneous and subcutaneous melanoma metastases (Fig. 1b). There was no evidence for distant metastatic disease."

## Event 171: drug_exposure
- Description: The patient received 4 cycles of ipilimumab at 3 mg/kg once every 3 weeks.
- Event date: NONE
- Relative time: NONE
- Stored/source precision: unknown / APPROXIMATE
- Relation to regression: BEFORE
  - Evidence 965: page 2, section Case Presentation, type OBSERVED_FACT
  - Quote: "Between December 2012 and February 2013 the patient received 4 cycles of the anti-CTLA-4 monoclonal antibody ipilimumab, at the standard dose of 3 mg/kg given once every 3 weeks, which he intially tolerated well except for intermittent low-grade diarrhea and fatigue."

## Event 172: other
- Description: The patient developed anemia with hemoglobin 6.7 g/dl requiring transfusions; bone marrow biopsy suggested pure red cell aplasia as the most likely etiology.
- Event date: NONE
- Relative time: NONE
- Stored/source precision: unknown / APPROXIMATE
- Relation to regression: BEFORE
  - Evidence 966: page 2, section Case Presentation, type AUTHOR_INTERPRETATION
  - Quote: "In April 2013, he developed anemia with a hemoglobin of 6.7 g/dl requiring transfusions. An extensive work up including bone marrow biopsy suggested pure red cell aplasia, which is rare however has been previously described after treatment with CTLA-4 blockade [4], as the most likely etiology."

## Event 173: treatment
- Description: The patient was treated with dexamethasone for 4 days and then intravenous immunoglobulin, without reticulocytosis or normalization of hemoglobin.
- Event date: NONE
- Relative time: after anemia developed in April 2013
- Stored/source precision: unknown / RELATIVE
- Relation to regression: BEFORE
  - Evidence 967: page 2, section Case Presentation, type OBSERVED_FACT
  - Quote: "The patient was treated with a pulse of dexamethasone for 4 days at 1 mg/kg-day, with no change in his transfusion requirements and no rise of the reticulocyte count, then intravenous immunoglobulin (IVIg), with no reticulocytosis and no normalization of his hemoglobin."

## Event 174: diagnosis
- Description: Cytogenetics showed del(5q) in 5/20 cells, consistent with myelodysplastic syndrome.
- Event date: NONE
- Relative time: after the April 2013 anemia workup
- Stored/source precision: unknown / RELATIVE
- Relation to regression: BEFORE
  - Evidence 968: page 2, section Case Presentation, type OBSERVED_FACT
  - Quote: "His cytogenetics showed 5/20 cells positive for del(5q), consistent with myelodysplastic syndrome"

## Event 175: drug_exposure
- Description: The patient received lenalidomide, which was stopped due to renal toxicity and substantial improvement of anemia.
- Event date: NONE
- Relative time: NONE
- Stored/source precision: unknown / APPROXIMATE
- Relation to regression: BEFORE
  - Evidence 969: page 2, section Case Presentation, type OBSERVED_FACT
  - Quote: "he therefore received a course of lenalidomide between April and June 2013, which was eventually stopped 2nd to renal toxicity and substantial improvement of the anemia."

## Event 176: tumor_progression
- Description: There was continued slow growth of the right lower-extremity metastases.
- Event date: NONE
- Relative time: NONE
- Stored/source precision: unknown / APPROXIMATE
- Relation to regression: BEFORE
  - Evidence 970: page 2, section Case Presentation, type OBSERVED_FACT
  - Quote: "Between December 2012 and December 2013 there was continued slow growth of the right lower extremity metastases."

## Event 177: tumor_progression
- Description: Accelerated disease progression was noted, with enlargement of pre-existing right lower-extremity nodules and development of new nodules.
- Event date: NONE
- Relative time: NONE
- Stored/source precision: unknown / APPROXIMATE
- Relation to regression: BEFORE
  - Evidence 971: page 2, section Case Presentation, type OBSERVED_FACT
  - Quote: "By January 2014 accelerated progression of disease with substantial increase in the size of pre-existent right lower extremity skin nodules as well as development of new nodules was noted."

## Event 178: infection
- Description: A lateral right popliteal nodule enlarged to approximately 4 cm over a few weeks, became ulcerated, and was chronically infected.
- Event date: NONE
- Relative time: over a few weeks
- Stored/source precision: unknown / APPROXIMATE
- Relation to regression: BEFORE
  - Evidence 972: page 2, section Case Presentation, type OBSERVED_FACT
  - Quote: "A nodule in the lateral right popliteal area enlarged to a size of ca. 4 cm over a few weeks and became ulcerated and chronically infected."

## Event 179: surgery
- Description: A palliative resection of the fast-growing dominant nodule was performed.
- Event date: NONE
- Relative time: NONE
- Stored/source precision: unknown / APPROXIMATE
- Relation to regression: BEFORE
  - Evidence 973: page 2, section Case Presentation, type OBSERVED_FACT
  - Quote: "Given the lack of distant metastatic disease and the absence of compelling systemic treatment options, in February 2014 a palliative resection of the fast growing dominant nodule was performed."

## Event 180: infection
- Description: After the February 2014 resection, the patient had wound dehiscence and recurring infections requiring intense wound care for 3 months.
- Event date: NONE
- Relative time: postoperative course after the February 2014 resection; over a period of 3 months
- Stored/source precision: unknown / RELATIVE
- Relation to regression: BEFORE
  - Evidence 974: page 2, section Case Presentation, type OBSERVED_FACT
  - Quote: "The patient had a complicated postoperative course with wound dehiscence and recurring infections requiring intense wound care over a period of 3 months."

## Event 181: tumor_progression
- Description: During the protracted postoperative course, multiple skin metastases grew further and new lesions emerged clinically and on restaging scans; no distant metastases were evident.
- Event date: NONE
- Relative time: during the protracted postoperative course after the February 2014 resection
- Stored/source precision: unknown / RELATIVE
- Relation to regression: BEFORE
  - Evidence 975: page 2, section Case Presentation, type OBSERVED_FACT
  - Quote: "During the protracted postoperative course there was further growth of multiple skin metastases with emergence of new lesions both clinically and on restaging scans while no distant metastases were evident."

## Event 182: surgery
- Description: Another palliative resection of a fast-growing right medial knee nodule was performed.
- Event date: NONE
- Relative time: NONE
- Stored/source precision: unknown / APPROXIMATE
- Relation to regression: BEFORE
  - Evidence 976: page 2, section Case Presentation, type OBSERVED_FACT
  - Quote: "Another palliative resection of a fast growing nodule on the right medial knee was performed in August 2014."

## Event 183: tumor_regression
- Description: The patient first noted shrinkage of several skin nodules.
- Event date: NONE
- Relative time: almost 2 years after the first treatment with ipilimumab and 9 months after the first of 2 palliative resections
- Stored/source precision: approximate / APPROXIMATE
- Relation to regression: DURING
  - Evidence 977: page 2, section Case Presentation, type OBSERVED_FACT
  - Quote: "By November 2014, almost 2 years after the first treatment with ipilimumab and 9 months after the first of 2 palliative resections, the patient noted shrinkage of several skin nodules."

## Event 184: tumor_regression
- Description: A restaging PET/CT showed a mixed response.
- Event date: NONE
- Relative time: NONE
- Stored/source precision: unknown / APPROXIMATE
- Relation to regression: DURING
  - Evidence 978: page 2, section Case Presentation, type OBSERVED_FACT
  - Quote: "A restaging PET/CT performed in December 2014 showed a mixed response."

## Event 185: tumor_regression
- Description: All non-resected in-transit metastases had completely disappeared clinically.
- Event date: NONE
- Relative time: 2 years after completion of ipilimumab
- Stored/source precision: unknown / APPROXIMATE
- Relation to regression: DURING
  - Evidence 980: page 1, section Abstract, type OBSERVED_FACT
  - Quote: "Case presentation: Here, we present the case of a patient with in transit metastases from cutaneous melanoma on his right lower extremity who achieved complete regression of all metastatic lesions 13 months after the first of two consecutive palliative resections of dominant masses and more than two years after treatment with ipilimumab."
  - Evidence 979: page 2, section Case Presentation, type AUTHOR_INTERPRETATION
  - Quote: "By March 2015 (2 years after completion of ipilimumab) all non-resected in transit metastases had completely disappeared clinically; radiographically, in May 2015 there was a continued mixed response with most lesions reduced in size."

## Event 186: tumor_regression
- Description: Radiographically, there was a continued mixed response, with most lesions reduced in size.
- Event date: NONE
- Relative time: NONE
- Stored/source precision: unknown / APPROXIMATE
- Relation to regression: DURING
  - Evidence 981: page 2, section Case Presentation, type AUTHOR_INTERPRETATION
  - Quote: "radiographically, in May 2015 there was a continued mixed response with most lesions reduced in size."

## Event 187: tumor_regression
- Description: All in-transit metastases had resolved clinically and radiographically, with complete clinical and radiographic response.
- Event date: NONE
- Relative time: NONE
- Stored/source precision: unknown / APPROXIMATE
- Relation to regression: DURING
  - Evidence 982: page 2, section Case Presentation, type OBSERVED_FACT
  - Quote: "By August 2016, all in transit metastases had resolved both clinically and radiographically and the patient remains in a complete clinical and radio-graphic response (Fig. 1c, d)."

# Lesion Map

## February 2014 and August 2014 surgically resected in-transit metastases
- Scope: LESION
- Roles: UNKNOWN
- Observation 289: CD3+ and CD8+ T-cell infiltration | REPORTED/PRESENT | brisk infiltration with CD3+ and CD8+ T cells in both surgically resected in transit metastases

## all right lower-extremity in-transit metastases
- Scope: LESION
- Roles: REGRESSING_TARGET
- Observation 288: in-transit metastases | REPORTED_ABSENT/ABSENT | all in transit metastases had resolved both clinically and radiographically

## excised right-leg lesion
- Scope: LESION
- Roles: UNKNOWN
- Observation 274: excisional biopsy diagnosis | REPORTED/PRESENT | malignant melanoma with focal necrosis
- Observation 275: excised lesion morphology and size | REPORTED/PRESENT | purple, tender, 2.7 × 2.5 × 1.5 cm in size

## in-transit metastasis removed in August 2014
- Scope: LESION
- Roles: UNKNOWN
- Observation 292: tumor necrosis in August 2014 resected metastasis | REPORTED_ABSENT/ABSENT | no necrosis was seen

## in-transit metastasis resected in February 2014
- Scope: LESION
- Roles: UNKNOWN
- Observation 290: tumor necrosis in February 2014 resected metastasis | REPORTED/PRESENT | highly necrotic
- Observation 291: viable tumor in February 2014 resected metastasis | REPORTED/PRESENT | some areas of viable tumor as evident by SOX10 staining

## lateral right popliteal nodule
- Scope: LESION
- Roles: UNKNOWN
- Observation 283: lateral right popliteal nodule | REPORTED/INCREASED | enlarged to a size of ca. 4 cm over a few weeks and became ulcerated and chronically infected

## melanoma
- Scope: LESION
- Roles: UNKNOWN
- Observation 278: BRAFV600 status | REPORTED_ABSENT/ABSENT | wild-type

## multiple right lower-extremity skin metastases
- Scope: LESION
- Roles: UNKNOWN
- Observation 284: multiple skin metastases during postoperative course | REPORTED/INCREASED | further growth of multiple skin metastases with emergence of new lesions both clinically and on restaging scans

## multiple right-leg cutaneous lesions
- Scope: LESION
- Roles: UNKNOWN
- Observation 273: size of right-leg cutaneous lesions | REPORTED/INCREASED | growing in size over the preceding 3 years

## multiple right-leg cutaneous nodules
- Scope: LESION
- Roles: UNKNOWN
- Observation 272: right-leg cutaneous nodules | REPORTED/PRESENT | multiple cutaneous nodules on his right leg

## non-resected right lower-extremity in-transit metastases
- Scope: LESION
- Roles: REGRESSING_TARGET
- Observation 287: non-resected in-transit metastases | REPORTED_ABSENT/ABSENT | completely disappeared clinically

## right lower-extremity cutaneous and subcutaneous lesions from mid thigh to ankle, including dominant mass lateral to right fibular head
- Scope: LESION
- Roles: UNKNOWN
- Observation 276: right lower-extremity melanoma metastases on PET/CT | REPORTED/PRESENT | a dominant soft tissue mass lateral to the right fibular head with numerous additional soft tissue nodules extending from the right mid thigh anteriorly to the level of the ankle, compatible with multiple cutaneous and subcutaneous melanoma metastases

## right lower-extremity metastases
- Scope: LESION
- Roles: UNKNOWN
- Observation 281: right lower-extremity metastasis growth | REPORTED/INCREASED | continued slow growth

## right lower-extremity skin nodules
- Scope: LESION
- Roles: UNKNOWN
- Observation 282: right lower-extremity skin nodules | REPORTED/INCREASED | accelerated progression of disease with substantial increase in the size of pre-existent right lower extremity skin nodules as well as development of new nodules

## several right lower-extremity skin nodules
- Scope: LESION
- Roles: REGRESSING_TARGET
- Observation 285: several skin nodules | REPORTED/DECREASED | shrinkage

# Biological States

## Observation 279: hemoglobin
- Category: OTHER
- Value: 6.7 g/dl
- Status / direction: REPORTED / UNKNOWN
- Semantics: LAB_MEASUREMENT
- Time relation: BEFORE_REGRESSION
- Scope / lesion: SYSTEMIC / NONE
- Regression role: UNKNOWN
  - Evidence 995: page 2, section Case Presentation, type OBSERVED_FACT
  - Quote: "In April 2013, he developed anemia with a hemoglobin of 6.7 g/dl requiring transfusions."

## Observation 290: tumor necrosis in February 2014 resected metastasis
- Category: PATHOLOGIC
- Value: highly necrotic
- Status / direction: REPORTED / PRESENT
- Semantics: PATHOLOGIC_FINDING
- Time relation: BEFORE_REGRESSION
- Scope / lesion: LESION / in-transit metastasis resected in February 2014
- Regression role: UNKNOWN
  - Evidence 1007: page 2, section Case Presentation, type OBSERVED_FACT
  - Quote: "The metastasis which was resected in February 2014 was highly necrotic"

# Disease Phenotypes

## Observation 272: right-leg cutaneous nodules
- Category: PATHOLOGIC
- Value: multiple cutaneous nodules on his right leg
- Status / direction: REPORTED / PRESENT
- Semantics: MORPHOLOGIC_FINDING
- Time relation: BEFORE_REGRESSION
- Scope / lesion: LESION / multiple right-leg cutaneous nodules
- Regression role: UNKNOWN
  - Evidence 987: page 1, section Case Presentation, type OBSERVED_FACT
  - Quote: "presented with multiple cutaneous nodules on his right leg."

## Observation 273: size of right-leg cutaneous lesions
- Category: PATHOLOGIC
- Value: growing in size over the preceding 3 years
- Status / direction: REPORTED / INCREASED
- Semantics: MORPHOLOGIC_FINDING
- Time relation: BEFORE_REGRESSION
- Scope / lesion: LESION / multiple right-leg cutaneous lesions
- Regression role: UNKNOWN
  - Evidence 988: page 1, section Case Presentation, type OBSERVED_FACT
  - Quote: "The lesions had been growing in size over the preceding 3 years"

## Observation 275: excised lesion morphology and size
- Category: PATHOLOGIC
- Value: purple, tender, 2.7 × 2.5 × 1.5 cm in size
- Status / direction: REPORTED / PRESENT
- Semantics: MORPHOLOGIC_FINDING
- Time relation: BEFORE_REGRESSION
- Scope / lesion: LESION / excised right-leg lesion
- Regression role: UNKNOWN
  - Evidence 990: page 1, section Case Presentation, type OBSERVED_FACT
  - Quote: "The lesion was described as purple, tender, 2.7 × 2.5 × 1.5 cm in size."

## Observation 281: right lower-extremity metastasis growth
- Category: PATHOLOGIC
- Value: continued slow growth
- Status / direction: REPORTED / INCREASED
- Semantics: MORPHOLOGIC_FINDING
- Time relation: BEFORE_REGRESSION
- Scope / lesion: LESION / right lower-extremity metastases
- Regression role: UNKNOWN
  - Evidence 997: page 2, section Case Presentation, type OBSERVED_FACT
  - Quote: "Between December 2012 and December 2013 there was continued slow growth of the right lower extremity metastases."

## Observation 282: right lower-extremity skin nodules
- Category: PATHOLOGIC
- Value: accelerated progression of disease with substantial increase in the size of pre-existent right lower extremity skin nodules as well as development of new nodules
- Status / direction: REPORTED / INCREASED
- Semantics: MORPHOLOGIC_FINDING
- Time relation: BEFORE_REGRESSION
- Scope / lesion: LESION / right lower-extremity skin nodules
- Regression role: UNKNOWN
  - Evidence 998: page 2, section Case Presentation, type OBSERVED_FACT
  - Quote: "By January 2014 accelerated progression of disease with substantial increase in the size of pre-existent right lower extremity skin nodules as well as development of new nodules was noted."

## Observation 283: lateral right popliteal nodule
- Category: PATHOLOGIC
- Value: enlarged to a size of ca. 4 cm over a few weeks and became ulcerated and chronically infected
- Status / direction: REPORTED / INCREASED
- Semantics: MORPHOLOGIC_FINDING
- Time relation: BEFORE_REGRESSION
- Scope / lesion: LESION / lateral right popliteal nodule
- Regression role: UNKNOWN
  - Evidence 999: page 2, section Case Presentation, type OBSERVED_FACT
  - Quote: "A nodule in the lateral right popliteal area enlarged to a size of ca. 4 cm over a few weeks and became ulcerated and chronically infected."

## Observation 284: multiple skin metastases during postoperative course
- Category: PATHOLOGIC
- Value: further growth of multiple skin metastases with emergence of new lesions both clinically and on restaging scans
- Status / direction: REPORTED / INCREASED
- Semantics: MORPHOLOGIC_FINDING
- Time relation: BEFORE_REGRESSION
- Scope / lesion: LESION / multiple right lower-extremity skin metastases
- Regression role: UNKNOWN
  - Evidence 1000: page 2, section Case Presentation, type OBSERVED_FACT
  - Quote: "During the protracted postoperative course there was further growth of multiple skin metastases with emergence of new lesions both clinically and on restaging scans"

## Observation 285: several skin nodules
- Category: PATHOLOGIC
- Value: shrinkage
- Status / direction: REPORTED / DECREASED
- Semantics: MORPHOLOGIC_FINDING
- Time relation: DURING_REGRESSION
- Scope / lesion: LESION / several right lower-extremity skin nodules
- Regression role: REGRESSING_TARGET
  - Evidence 1001: page 2, section Case Presentation, type OBSERVED_FACT
  - Quote: "By November 2014, almost 2 years after the first treatment with ipilimumab and 9 months after the first of 2 palliative resections, the patient noted shrinkage of several skin nodules."

## Observation 287: non-resected in-transit metastases
- Category: PATHOLOGIC
- Value: completely disappeared clinically
- Status / direction: REPORTED_ABSENT / ABSENT
- Semantics: CLINICAL_FINDING
- Time relation: DURING_REGRESSION
- Scope / lesion: LESION / non-resected right lower-extremity in-transit metastases
- Regression role: REGRESSING_TARGET
  - Evidence 1003: page 2, section Case Presentation, type OBSERVED_FACT
  - Quote: "By March 2015 (2 years after completion of ipilimumab) all non-resected in transit metastases had completely disappeared clinically"

# Diagnostic Evidence

## Observation 274: excisional biopsy diagnosis
- Category: PATHOLOGIC
- Value: malignant melanoma with focal necrosis
- Status / direction: REPORTED / PRESENT
- Semantics: PATHOLOGIC_FINDING
- Time relation: BEFORE_REGRESSION
- Scope / lesion: LESION / excised right-leg lesion
- Regression role: UNKNOWN
  - Evidence 989: page 1, section Case Presentation, type OBSERVED_FACT
  - Quote: "An excisional biopsy was performed and revealed a malignant melanoma with focal necrosis."

## Observation 276: right lower-extremity melanoma metastases on PET/CT
- Category: PATHOLOGIC
- Value: a dominant soft tissue mass lateral to the right fibular head with numerous additional soft tissue nodules extending from the right mid thigh anteriorly to the level of the ankle, compatible with multiple cutaneous and subcutaneous melanoma metastases
- Status / direction: REPORTED / PRESENT
- Semantics: IMAGING_PROXY
- Time relation: BEFORE_REGRESSION
- Scope / lesion: LESION / right lower-extremity cutaneous and subcutaneous lesions from mid thigh to ankle, including dominant mass lateral to right fibular head
- Regression role: UNKNOWN
  - Evidence 991: page 1, section Case Presentation, type OBSERVED_FACT
  - Quote: "A PET/CT of the entire body demonstrated a dominant soft tissue mass lateral to the right fibular head with numerous additional soft tissue nodules extending from the right mid thigh anteriorly to the level of the ankle, compatible with multiple cutaneous and subcutaneous melanoma metastases"

## Observation 277: distant metastatic disease
- Category: PATHOLOGIC
- Value: no evidence for distant metastatic disease
- Status / direction: REPORTED_ABSENT / ABSENT
- Semantics: IMAGING_PROXY
- Time relation: BEFORE_REGRESSION
- Scope / lesion: SYSTEMIC / NONE
- Regression role: UNKNOWN
  - Evidence 992: page 1, section Case Presentation, type OBSERVED_FACT
  - Quote: "There was no evidence for distant metastatic disease."
  - Evidence 993: page 2, section Case Presentation, type OBSERVED_FACT
  - Quote: "while no distant metastases were evident."

## Observation 278: BRAFV600 status
- Category: GENETIC
- Value: wild-type
- Status / direction: REPORTED_ABSENT / ABSENT
- Semantics: PATHOLOGIC_FINDING
- Time relation: BEFORE_REGRESSION
- Scope / lesion: LESION / melanoma
- Regression role: UNKNOWN
  - Evidence 994: page 1, section Case Presentation, type OBSERVED_FACT
  - Quote: "BRAFV600 status was found to be wild-type."

## Observation 280: cytogenetics del(5q)
- Category: GENETIC
- Value: 5/20 cells positive for del(5q)
- Status / direction: REPORTED / PRESENT
- Semantics: LAB_MEASUREMENT
- Time relation: BEFORE_REGRESSION
- Scope / lesion: SYSTEMIC / NONE
- Regression role: UNKNOWN
  - Evidence 996: page 2, section Case Presentation, type OBSERVED_FACT
  - Quote: "His cytogenetics showed 5/20 cells positive for del(5q)"

## Observation 286: restaging PET/CT response
- Category: OTHER
- Value: mixed response
- Status / direction: REPORTED / MIXED
- Semantics: IMAGING_PROXY
- Time relation: DURING_REGRESSION
- Scope / lesion: OTHER / NONE
- Regression role: UNKNOWN
  - Evidence 1002: page 2, section Case Presentation, type OBSERVED_FACT
  - Quote: "A restaging PET/CT performed in December 2014 showed a mixed response."

## Observation 289: CD3+ and CD8+ T-cell infiltration
- Category: IMMUNE
- Value: brisk infiltration with CD3+ and CD8+ T cells in both surgically resected in transit metastases
- Status / direction: REPORTED / PRESENT
- Semantics: PATHOLOGIC_FINDING
- Time relation: BEFORE_REGRESSION
- Scope / lesion: LESION / February 2014 and August 2014 surgically resected in-transit metastases
- Regression role: UNKNOWN
  - Evidence 1006: page 2, section Case Presentation, type OBSERVED_FACT
  - Quote: "Dual immunohistochemical staining of CD3 and CD8 with the melanoma marker SOX10 demonstrated brisk infiltration with CD3+ and CD8+ T cells in both surgically resected in transit metastases"

## Observation 291: viable tumor in February 2014 resected metastasis
- Category: PATHOLOGIC
- Value: some areas of viable tumor as evident by SOX10 staining
- Status / direction: REPORTED / PRESENT
- Semantics: PATHOLOGIC_FINDING
- Time relation: BEFORE_REGRESSION
- Scope / lesion: LESION / in-transit metastasis resected in February 2014
- Regression role: UNKNOWN
  - Evidence 1008: page 2, section Case Presentation, type OBSERVED_FACT
  - Quote: "with some areas of viable tumor as evident by SOX10 staining"

## Observation 292: tumor necrosis in August 2014 resected metastasis
- Category: PATHOLOGIC
- Value: no necrosis was seen
- Status / direction: REPORTED_ABSENT / ABSENT
- Semantics: PATHOLOGIC_FINDING
- Time relation: BEFORE_REGRESSION
- Scope / lesion: LESION / in-transit metastasis removed in August 2014
- Regression role: UNKNOWN
  - Evidence 1009: page 2, section Case Presentation, type OBSERVED_FACT
  - Quote: "no necrosis was seen in the metastasis that was removed in August 2014."

# Clinical Context

None.

# Treatment Response

## Observation 288: in-transit metastases
- Category: PATHOLOGIC
- Value: all in transit metastases had resolved both clinically and radiographically
- Status / direction: REPORTED_ABSENT / ABSENT
- Semantics: CLINICAL_FINDING
- Time relation: AT_CONFIRMATION
- Scope / lesion: LESION / all right lower-extremity in-transit metastases
- Regression role: REGRESSING_TARGET
  - Evidence 1005: page 2, section Case Presentation, type OBSERVED_FACT
  - Quote: "By August 2016, all in transit metastases had resolved both clinically and radiographically and the patient remains in a complete clinical and radiographic response"

# Confounder Register

Presence records temporal co-occurrence only and is not a causal assignment.

## prior immunotherapy
- Status: PRESENT
- Temporal relation: BEFORE; time not stored
  - Evidence 965: page 2, section Case Presentation, type OBSERVED_FACT
  - Quote: "Between December 2012 and February 2013 the patient received 4 cycles of the anti-CTLA-4 monoclonal antibody ipilimumab, at the standard dose of 3 mg/kg given once every 3 weeks, which he intially tolerated well except for intermittent low-grade diarrhea and fatigue."

## recent surgery
- Status: PRESENT
- Temporal relation: BEFORE; time not stored
  - Evidence 973: page 2, section Case Presentation, type OBSERVED_FACT
  - Quote: "Given the lack of distant metastatic disease and the absence of compelling systemic treatment options, in February 2014 a palliative resection of the fast growing dominant nodule was performed."
- Temporal relation: BEFORE; time not stored
  - Evidence 976: page 2, section Case Presentation, type OBSERVED_FACT
  - Quote: "Another palliative resection of a fast growing nodule on the right medial knee was performed in August 2014."

## biopsy
- Status: PRESENT
- Temporal relation: BEFORE; time not stored
  - Evidence 963: page 1, section Case Presentation, type OBSERVED_FACT
  - Quote: "An excisional biopsy was performed and revealed a malignant melanoma with focal necrosis."

## infection
- Status: PRESENT
- Temporal relation: BEFORE; over a few weeks
  - Evidence 972: page 2, section Case Presentation, type OBSERVED_FACT
  - Quote: "A nodule in the lateral right popliteal area enlarged to a size of ca. 4 cm over a few weeks and became ulcerated and chronically infected."
- Temporal relation: BEFORE; postoperative course after the February 2014 resection; over a period of 3 months
  - Evidence 974: page 2, section Case Presentation, type OBSERVED_FACT
  - Quote: "The patient had a complicated postoperative course with wound dehiscence and recurring infections requiring intense wound care over a period of 3 months."

## vaccination
- Status: NOT_REPORTED
- Temporal relation: UNKNOWN
- Evidence: NONE

## radiotherapy
- Status: NOT_REPORTED
- Temporal relation: UNKNOWN
- Evidence: NONE

## systemic therapy
- Status: PRESENT
- Temporal relation: BEFORE; time not stored
  - Evidence 965: page 2, section Case Presentation, type OBSERVED_FACT
  - Quote: "Between December 2012 and February 2013 the patient received 4 cycles of the anti-CTLA-4 monoclonal antibody ipilimumab, at the standard dose of 3 mg/kg given once every 3 weeks, which he intially tolerated well except for intermittent low-grade diarrhea and fatigue."
- Temporal relation: BEFORE; after anemia developed in April 2013
  - Evidence 967: page 2, section Case Presentation, type OBSERVED_FACT
  - Quote: "The patient was treated with a pulse of dexamethasone for 4 days at 1 mg/kg-day, with no change in his transfusion requirements and no rise of the reticulocyte count, then intravenous immunoglobulin (IVIg), with no reticulocytosis and no normalization of his hemoglobin."
- Temporal relation: BEFORE; time not stored
  - Evidence 969: page 2, section Case Presentation, type OBSERVED_FACT
  - Quote: "he therefore received a course of lenalidomide between April and June 2013, which was eventually stopped 2nd to renal toxicity and substantial improvement of the anemia."

## alternative treatment
- Status: NOT_REPORTED
- Temporal relation: UNKNOWN
- Evidence: NONE

## other major clinical intervention
- Status: PRESENT
- Temporal relation: BEFORE; time not stored
  - Evidence 966: page 2, section Case Presentation, type AUTHOR_INTERPRETATION
  - Quote: "In April 2013, he developed anemia with a hemoglobin of 6.7 g/dl requiring transfusions. An extensive work up including bone marrow biopsy suggested pure red cell aplasia, which is rare however has been previously described after treatment with CTLA-4 blockade [4], as the most likely etiology."

# Author Interpretations

## Interpretation 1
- Statement: An extensive work up including bone marrow biopsy suggested pure red cell aplasia, which is rare however has been previously described after treatment with CTLA-4 blockade [4], as the most likely etiology.
- Rejection reason: Uses “suggested” and “most likely etiology”; this is an author diagnostic interpretation rather than a directly observed finding.
- Page / section: 2 / Case Presentation
- Quote: "An extensive work up including bone marrow biopsy suggested pure red cell aplasia, which is rare however has been previously described after treatment with CTLA-4 blockade [4], as the most likely etiology."

## Interpretation 2
- Statement: Dual immunohistochemical staining of CD3 and CD8 with the melanoma marker SOX10 demonstrated brisk infiltration with CD3+ and CD8+ T cells in both surgically resected in transit metastases, suggesting a T cell mediated immune response against the tumor in both samples (Fig. 2).
- Rejection reason: The phrase “suggesting a T cell mediated immune response” is an interpretation; the infiltration itself is retained as an observation.
- Page / section: 2 / Case Presentation
- Quote: "Dual immunohistochemical staining of CD3 and CD8 with the melanoma marker SOX10 demonstrated brisk infiltration with CD3+ and CD8+ T cells in both surgically resected in transit metastases, suggesting a T cell mediated immune response against the tumor in both samples (Fig. 2)."

## Interpretation 3
- Statement: Although the exact cause of our patient’s sudden onset of tumor regression, eventually leading to disappearance of all clinically and radiographically evident tumors, remains speculative, an immune related mechanism seems most plausible. We hypothesize that the operative trauma followed by the postoperative infections triggered an innate immune response similiar to a microbial immune adjuvant such as a Toll Like Receptor or a STING agonist [11, 12].
- Rejection reason: Explicitly speculative and hypothesized causal mechanism.
- Page / section: 3 / Conclusion
- Quote: "Although the exact cause of our patient’s sudden onset of tumor regression, eventually leading to disappearance of all clinically and radiographically evident tumors, remains speculative, an immune related mechanism seems most plausible. We hypothesize that the operative trauma followed by the postoperative infections triggered an innate immune response similiar to a microbial immune adjuvant such as a Toll Like Receptor or a STING agonist [11, 12]."

## Interpretation 4
- Statement: For our patient, it is intriguing to speculate that his exposure to ipilimumab almost 2 years prior to the onset of tumor regression also contributed to the tumor response.
- Rejection reason: Explicit speculation about treatment contribution; no causal inference is extracted.
- Page / section: 3 / Conclusion
- Quote: "For our patient, it is intriguing to speculate that his exposure to ipilimumab almost 2 years prior to the onset of tumor regression also contributed to the tumor response."

## Interpretation 5
- Statement: most lesions on radiography
- Rejection reason: Mechanistic or interpretive language cannot be an observation
- Page / section: 2 / Case Presentation
- Quote: "radiographically, in May 2015 there was a continued mixed response with most lesions reduced in size."

# Rejected Claims

No quote-verification failures.

# Validation Failures

- The first PHASE 2 attempt (run 38) was blocked by a legacy SQLite temporal CHECK constraint. A compatibility-only persistence fix was required; schema, rule, and prompts were unchanged.
- Reported approximate diagnosis and regression-confirmation dates remained in field_statuses but could not be persisted in the exact date columns.
- Chronic lesion infection and postoperative recurring infections were captured as Events but no CLINICAL_CONTEXT observation was produced.
- Measured brisk CD3+/CD8+ T-cell infiltration was classified as DIAGNOSTIC_EVIDENCE rather than BIOLOGICAL_STATE (observation 289).
- BRAF V600 wild-type was represented as REPORTED_ABSENT/ABSENT instead of a reported genetic state (observation 278).
- Complete spontaneous resolution of in-transit metastases was classified as TREATMENT_RESPONSE despite the delayed, causally unresolved setting (observation 288).
- One direct radiographic reduction statement was rejected as an author interpretation ('most lesions reduced in size').
- Grouped and overlapping right-leg lesion identifiers prevent a reliable count of anatomically distinct lesions; exact identifiers are not stable lesion identities.

# New Ontology Pressure Points

- Approximate month/year and 'by month/year' dates are preserved only in raw field status, not typed date columns.
- Observed infection functions as both a timed event and local/systemic clinical context, but the current observation layer omitted the latter.
- Immune-cell infiltration used diagnostically is simultaneously a measured biological state; one domain cannot express both roles.
- Wild-type genotype is a positive state, not reported absence.
- Delayed post-treatment regression cannot be labeled treatment response without encoding causal uncertainty.
- Multifocal in-transit disease requires lesion collections plus individual members, not free-text identifiers alone.
- Resected and non-resected lesion sets need persistent identities across pathology, surgery, imaging, and regression observations.
- Evidence-type fallback can preserve an incorrect LLM-declared AUTHOR_INTERPRETATION when direct-observation wording is not recognized.

# Validation Summary

- PHASE 2 status/run: partial / 39
- PHASE 3.1 status/run: partial / 40
- Stable versions: phase2.2.2 / phase2.2-adjudication-v4 / case v5 / timeline v3; phase3.1 / phase3.1-ontology-v4 / biological v2
- Case count: 1
- Event count: 21
- Exact lesion identifier count: 15
- Biological State count: 2
- Disease Phenotype count: 9
- Clinical Context count: 0
- Diagnostic Evidence count: 9
- Treatment Response count: 1
- Verified Evidence count: 79
- Rejected Evidence count: 5
- Quote failure count: 0
- Case UNCERTAIN/CONFLICTING count: 1
- Observation UNCERTAIN/CONFLICTING count: 0
- UNKNOWN direction count: 1
- UNKNOWN regression-role count: 18
- Ontology pressure point count: 8
